<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">PEN</journal-id>
<journal-id journal-id-type="hwp">sppen</journal-id>
<journal-id journal-id-type="nlm-ta">JPEN J Parenter Enteral Nutr</journal-id>
<journal-title>Journal of Parenteral and Enteral Nutrition</journal-title>
<issn pub-type="ppub">0148-6071</issn>
<issn pub-type="epub">1941-2444</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0148607112463245</article-id>
<article-id pub-id-type="publisher-id">10.1177_0148607112463245</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Effects of Probiotics in Early Enteral Nutrition on the Outcomes of Trauma</article-title>
<subtitle>A Meta-Analysis of Randomized Controlled Trials</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Gu</surname><given-names>Wan-Jie</given-names></name>
<degrees>MSc</degrees>
<xref ref-type="aff" rid="aff1-0148607112463245">1</xref>
<xref ref-type="fn" rid="fn1-0148607112463245">*</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Deng</surname><given-names>Teng</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0148607112463245">2</xref>
<xref ref-type="fn" rid="fn1-0148607112463245">*</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gong</surname><given-names>Yi-Zhen</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff3-0148607112463245">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Jing</surname><given-names>Rui</given-names></name>
<degrees>MSc</degrees>
<xref ref-type="aff" rid="aff3-0148607112463245">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Liu</surname><given-names>Jing-Chen</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0148607112463245">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0148607112463245"><label>1</label>Department of Anaesthesiology, the First Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi, People’s Republic of China</aff>
<aff id="aff2-0148607112463245"><label>2</label>Department of Head and Neck Surgery, the Affiliated Tumor Hospital, Guangxi Medical University, Nanning, Guangxi, People’s Republic of China</aff>
<aff id="aff3-0148607112463245"><label>3</label>Department of Hepatobiliary Surgery, the First Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi, People’s Republic of China</aff>
<author-notes>
<corresp id="corresp1-0148607112463245">Jing-Chen Liu, MD, Department of Anaesthesiology, the First Affiliated Hospital, Guangxi Medical University, 22 Shuangyong Road, Nanning 530021, Guangxi, People’s Republic of China. Email: <email>jingchenliu1964@yahoo.com.cn</email>.</corresp>
<fn fn-type="equal" id="fn1-0148607112463245">
<label>*</label>
<p>These authors contributed equally to this work.</p>
</fn>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2013</year>
</pub-date>
<volume>37</volume>
<issue>3</issue>
<fpage>310</fpage>
<lpage>317</lpage>
<history>
<date date-type="received">
<day>6</day>
<month>7</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>9</day>
<month>8</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 American Society for Parenteral and Enteral Nutrition</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The American Society for Parenteral and Enteral Nutrition</copyright-holder>
</permissions>
<abstract>
<p><italic>Background</italic>: The role of probiotics in trauma patients remains unclear. We undertook a meta-analysis of published randomized controlled trials (RCTs) to assess the effects of probiotics on the clinical outcomes of trauma patients. <italic>Methods</italic>: A systematic electronic literature search was conducted to identify RCTs comparing the use of probiotics with a control in trauma patients. Results were expressed as risk ratios (RRs) or standardized mean differences (SMDs) with accompanying 95% confidence intervals (CIs). The primary outcome measurement was the incidence of nosocomial infections. Secondary outcome measurements included the incidence of ventilator-associated pneumonia (VAP), length of intensive care unit (ICU) stay, and mortality. The meta-analysis was performed with the fixed-effect or random-effect model according to the heterogeneity. <italic>Results</italic>: Five studies involving 281 patients met our inclusion criteria. The use of probiotics was associated with a reduction in the incidence of nosocomial infections (5 trials; RR, 0.65; 95% CI, 0.45–0.94, <italic>P</italic> = .02), VAP (3 trials; RR, 0.59; 95% CI, 0.42–0.81, <italic>P</italic> = .001), and length of ICU stay (2 trials; SMD, −0.71; 95% CI, −1.09 to −0.34, <italic>P</italic> &lt; .001) but no reduction in mortality (4 trials; RR, 0.63; 95% CI, 0.32–1.26, <italic>P</italic> = .19). <italic>Conclusions</italic>: The use of probiotics is associated with a reduction in the incidence of nosocomial infections, VAP, and length of ICU stay but is not associated with an overall mortality advantage. However, the results should be interpreted cautiously due to the heterogeneity among study designs. Further large-scale, well-designed RCTs are needed.</p>
</abstract>
<kwd-group>
<kwd>probiotics</kwd>
<kwd>enteral nutrition</kwd>
<kwd>trauma</kwd>
<kwd>meta-analysis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0148607112463245">
<title>Background</title>
<p>Probiotics are commercially available live microorganisms (essentially <italic>Lactobacilli</italic> and <italic>Bifidobacterium</italic>) and exert health-promoting effects for the host.<sup><xref ref-type="bibr" rid="bibr1-0148607112463245">1</xref></sup> The effects of probiotics are attributed to their capacity to balance gut microbiota, improve gastrointestinal barrier function, and modulate local and systemic immune functions.<sup><xref ref-type="bibr" rid="bibr2-0148607112463245">2</xref></sup> They have been used extensively in various patient groups, including critically ill patients, patients undergoing abdominal surgery, and patients with pancreatitis.<sup><xref ref-type="bibr" rid="bibr3-0148607112463245">3</xref><xref ref-type="bibr" rid="bibr4-0148607112463245"/><xref ref-type="bibr" rid="bibr5-0148607112463245"/>-<xref ref-type="bibr" rid="bibr6-0148607112463245">6</xref></sup> The use of probiotics has been demonstrated to significantly reduce the incidence of ventilator-associated pneumonia (VAP) in critically ill patients<sup><xref ref-type="bibr" rid="bibr4-0148607112463245">4</xref></sup> and to significantly reduce postoperative infection after abdominal surgery.<sup><xref ref-type="bibr" rid="bibr5-0148607112463245">5</xref></sup></p>
<p>Trauma represents a considerable public health problem with significant personal and societal costs.<sup><xref ref-type="bibr" rid="bibr7-0148607112463245">7</xref></sup> Major trauma is the second most important condition for children and the fourth most important condition for adults treated by emergency medical service providers.<sup><xref ref-type="bibr" rid="bibr8-0148607112463245">8</xref></sup> Major trauma patients experience a 20% mortality rate overall, and many survivors are left with permanent disability.<sup><xref ref-type="bibr" rid="bibr9-0148607112463245">9</xref></sup> Moreover, for trauma patients who survive longer than 3 days, infection is second only to severe head injury as the leading cause of death. This is the result of multiple factors, including increased catabolism, decreased immune function, and gut-barrier malfunction.<sup><xref ref-type="bibr" rid="bibr10-0148607112463245">10</xref></sup></p>
<p>Nowadays, there are published randomized controlled trials (RCTs) regarding the use of probiotics in trauma patients. However, these studies have a modest sample size and convey mixed and inconclusive results. Thus, we undertook a meta-analysis of published RCTs conducted in trauma patients to determine whether the use of probiotics compared with a control reduces complications such as nosocomial infections and VAP, length of intensive care unit (ICU) stay, and mortality.</p>
</sec>
<sec id="section2-0148607112463245" sec-type="methods">
<title>Methods</title>
<sec id="section3-0148607112463245">
<title>Search Strategy</title>
<p>PubMed and EMBASE databases (from inception to April 2012) were searched to identify RCTs comparing the use of probiotics with a control in trauma patients. The structured search strategies used the following format of search terms: (prebiotic* OR probiotic* OR synbiotic* OR lactobacillus OR bifidobacterium OR lactobacilli) AND (trauma OR injury OR injuries OR wound OR wounds). The search was limited to human subjects and RCTs. No language restriction was imposed. In addition, the reference lists of identified studies were manually checked to identify other potentially eligible trials. This process was performed iteratively until no additional articles could be identified.</p>
</sec>
<sec id="section4-0148607112463245">
<title>Inclusion and Exclusion Criteria</title>
<p>Studies were considered acceptable for inclusion in the meta-analysis if they met the following criteria: (1) trauma, including injury to organs or physical damage to the body caused by violence, accident, or fracture and burns; (2) RCT; (3) an enteral pre-, pro-, or synbiotic compared with a control; and (4) 1 or more of the following clinical outcomes reported: nosocomial infections, length of ICU stay, VAP, and mortality.</p>
<p>Trials were excluded if they (1) were abstracts, letters, or meeting proceedings; (2) had repeated data or did not report outcomes of interest; and (3) enrolled patients with drug-induced injury or surgical incision.</p>
</sec>
<sec id="section5-0148607112463245">
<title>Data Extraction and Outcome Measures</title>
<p>Two authors (W.-J.G. and Y.-Z.G.) independently extracted the following data: first author, year of publication, number of patients, patient characteristics, study design/Jadad score, probiotics group (dosage, route, and duration), control group (placebo or other), definition of nosocomial infections, diagnosis of VAP, the incidence of nosocomial infections, and other secondary outcomes data. Extracted data were entered into a standardized Excel file. Any disagreements were resolved by discussion and consensus.</p>
<p>The primary outcome measurement was the incidence of nosocomial infections. Nosocomial infections were defined according to the standard definition by the Centers for Disease Control and Prevention (CDC).<sup><xref ref-type="bibr" rid="bibr11-0148607112463245">11</xref></sup> Secondary outcome measurements included the incidence of VAP, length of ICU stay, and mortality. The definition of VAP varied across studies; no standard definition was used in reported studies.</p>
</sec>
<sec id="section6-0148607112463245">
<title>Quality Assessment</title>
<p>The methodological quality of each trial was evaluated using the Jadad scale.<sup><xref ref-type="bibr" rid="bibr12-0148607112463245">12</xref></sup> The scale consists of 3 items describing randomization (0–2 points), blinding (0–2 points), and dropouts and withdrawals (0–1 points) in the report of an RCT. A score of 1 is given for each of the points described. A further point is obtained where the method of randomization and/or blinding is given and is appropriate, and a point is deducted where it is inappropriate. The quality scale ranges from 0–5 points. Higher scores indicate better reporting. The studies are said to be of low quality if the Jadad score is ≤2 and high quality if the score is ≥3.<sup><xref ref-type="bibr" rid="bibr13-0148607112463245">13</xref></sup></p>
</sec>
<sec id="section7-0148607112463245">
<title>Statistical Analyses</title>
<p>Differences were expressed as risk ratios (RRs) with 95% confidence intervals (CIs) for dichotomous outcomes and standardized mean differences (SMDs) with 95% CIs for continuous outcomes. Heterogeneity across studies was tested by using the <italic>I</italic><sup>2</sup> statistic, which is a quantitative measure of inconsistency across studies. Studies with an <italic>I</italic><sup>2</sup> statistic of 25%–50% are considered to have low heterogeneity, those with an <italic>I</italic><sup>2</sup> statistic of 50%–75% have moderate heterogeneity, and those with an <italic>I</italic><sup>2</sup> statistic of &gt;75% have a high degree of heterogeneity.<sup><xref ref-type="bibr" rid="bibr14-0148607112463245">14</xref></sup> An <italic>I</italic><sup>2</sup> value greater than 50% indicates significant heterogeneity.<sup><xref ref-type="bibr" rid="bibr15-0148607112463245">15</xref></sup> A fixed-effects model was used, and a random-effects model was used in the case of significant heterogeneity (<italic>I</italic><sup>2</sup> &gt; 50%). Because patient characteristics, study designs, and other confounding factors were not consistent between studies, we further conducted sensitivity analyses to explore possible explanations for heterogeneity and to examine the influence of various exclusion criterions on the overall pooled estimate. The sensitivity analyses were performed only for nosocomial infections because of rather small numbers of studies for other outcomes.</p>
<p>The presence of publication bias was assessed by using the Begg and Egger tests.<sup><xref ref-type="bibr" rid="bibr16-0148607112463245">16</xref>,<xref ref-type="bibr" rid="bibr17-0148607112463245">17</xref></sup> A <italic>P</italic> value &lt;.05 was judged as statistically significant, except where otherwise specified. All statistical analyses were performed using STATA version 11.0 (StataCorp, College Station, TX).</p>
</sec>
</sec>
<sec id="section8-0148607112463245" sec-type="results">
<title>Results</title>
<sec id="section9-0148607112463245">
<title>Study Identification and Selection</title>
<p>An initial database search identified a total of 66 RCTs. Fourteen RCTs were excluded because of duplicate studies, and 43 RCTs were excluded based on the titles and abstracts. The remaining 9 full-text articles were reviewed for more detailed evaluation; 3 of them were also excluded because 1 was letter to the editor,<sup><xref ref-type="bibr" rid="bibr18-0148607112463245">18</xref></sup> 1 study was in Chinese,<sup><xref ref-type="bibr" rid="bibr19-0148607112463245">19</xref></sup> and 1 study did not report outcomes of interest.<sup><xref ref-type="bibr" rid="bibr20-0148607112463245">20</xref></sup> An additional RCT was excluded because of repeated data.<sup><xref ref-type="bibr" rid="bibr21-0148607112463245">21</xref></sup> Finally, 5 RCTs that met our inclusion criteria were included in the present meta-analysis.<sup><xref ref-type="bibr" rid="bibr22-0148607112463245">22</xref><xref ref-type="bibr" rid="bibr23-0148607112463245"/><xref ref-type="bibr" rid="bibr24-0148607112463245"/><xref ref-type="bibr" rid="bibr25-0148607112463245"/>-<xref ref-type="bibr" rid="bibr26-0148607112463245">26</xref></sup> The flowchart of studies included in the meta-analysis is shown in <xref ref-type="fig" rid="fig1-0148607112463245">Figure 1</xref>.</p>
<fig id="fig1-0148607112463245" position="float">
<label>Figure 1.</label>
<caption><p>Flowchart of studies included in meta-analysis. RCT, randomized controlled trial.</p></caption>
<graphic xlink:href="10.1177_0148607112463245-fig1.tif"/>
</fig>
</sec>
<sec id="section10-0148607112463245">
<title>Characteristics of the Studies</title>
<p>The main characteristics of the 5 RCTs included in the meta-analysis are presented in <xref ref-type="table" rid="table1-0148607112463245">Table 1</xref>, and the outcome data of each included trial are described in <xref ref-type="table" rid="table2-0148607112463245">Table 2</xref>. These studies were published between 2004 and 2011. The size of the RCT ranged from 20–113 (total 281). Among the 5 studies included here, all reported nosocomial infections events,<sup><xref ref-type="bibr" rid="bibr22-0148607112463245">22</xref><xref ref-type="bibr" rid="bibr23-0148607112463245"/><xref ref-type="bibr" rid="bibr24-0148607112463245"/><xref ref-type="bibr" rid="bibr25-0148607112463245"/>-<xref ref-type="bibr" rid="bibr26-0148607112463245">26</xref></sup> 4 reported mortality events,<sup><xref ref-type="bibr" rid="bibr22-0148607112463245">22</xref>,<xref ref-type="bibr" rid="bibr24-0148607112463245">24</xref><xref ref-type="bibr" rid="bibr25-0148607112463245"/>-<xref ref-type="bibr" rid="bibr26-0148607112463245">26</xref></sup> and 3 reported VAP<sup><xref ref-type="bibr" rid="bibr24-0148607112463245">24</xref><xref ref-type="bibr" rid="bibr25-0148607112463245"/>-<xref ref-type="bibr" rid="bibr26-0148607112463245">26</xref></sup> and length of ICU stay.<sup><xref ref-type="bibr" rid="bibr22-0148607112463245">22</xref>,<xref ref-type="bibr" rid="bibr24-0148607112463245">24</xref>,<xref ref-type="bibr" rid="bibr26-0148607112463245">26</xref></sup> The quality of the included studies was assessed by the Jadad score. The median Jadad score of the studies included was 3 (range, 2–4).</p>
<table-wrap id="table1-0148607112463245" position="float">
<label>Table 1.</label>
<caption><p>Main Characteristics of Randomized Controlled Trials Included in the Meta-Analysis of Probiotics in Trauma Patients.</p></caption>
<graphic alternate-form-of="table1-0148607112463245" xlink:href="10.1177_0148607112463245-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">First Author (Year of Publication)</th>
<th align="center">No. of Patients (Probiotics/Control)</th>
<th align="center">Study Design/ Jadad Score</th>
<th align="center">Patient Characteristics</th>
<th align="center">Probiotic Group</th>
<th align="center">Control Group</th>
<th align="center">Definition of Nosocomial Infections</th>
<th align="center">Diagnosis of VAP</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top">Falcao de Arruda (2004)<sup><xref ref-type="bibr" rid="bibr22-0148607112463245">22</xref></sup></td>
<td valign="top">20 (10/10)</td>
<td valign="top">RCT/2</td>
<td valign="top">Brain injury alone patients, ages 16–50 years, requiring ICU treatment and enteral feeding, with Glasgow score between 5 and 12 and TISS score &gt;20</td>
<td valign="top">A pure polymeric diet with 30 g of glutamine and 240 mL of fermented milk with the probiotic strain <italic>Lactobacillus johnsonii</italic>, once daily, via an enteral route, for 5–14 d</td>
<td valign="top">A pure polymeric diet</td>
<td valign="top">Unclear</td>
<td valign="top">NA</td>
</tr>
<tr>
<td valign="top">Olguin (2005)<sup><xref ref-type="bibr" rid="bibr23-0148607112463245">23</xref></sup></td>
<td valign="top">31 (16/15)</td>
<td valign="top">RCT (double-blind)/3</td>
<td valign="top">Burn patients, ages 14–70 years, with second- and/or third-degree burn injuries according to the Converse Smith classification equivalent to 5%–40% of the total body surface area and who were hospitalized within the first 24 h following their injury</td>
<td valign="top">3 g oligofructose (a prebiotic), twice daily, which began after the first permeability test and was administered during the following 15 d</td>
<td valign="top">Twice daily either 3 g sucrose dissolved in a glass of water or incorporated into food</td>
<td valign="top">Unclear</td>
<td valign="top">NA</td>
</tr>
<tr>
<td valign="top">Kotzampassi (2006)<sup><xref ref-type="bibr" rid="bibr24-0148607112463245">24</xref></sup></td>
<td valign="top">65 (35/30)</td>
<td valign="top">RCT (double-blind)/4</td>
<td valign="top">Multiple injured patients, age &gt;18 years, having a long ICU stay and needing to be mechanically ventilated or under ventilatory support, with a life expectancy of more than 15 d</td>
<td valign="top">10<sup>11</sup> CFU Synbiotic 2000FORTEP containing <italic>Pediococcus pentosaceus</italic> 5–33:3, <italic>Leuconostoc mesenteroides</italic> 32–77:1, <italic>Lactobacillus paracasei</italic> ssp 19, and <italic>Lactobacillus plantarum</italic> 2362, once daily, via a nasogastric tube or through gastrostomy, for 15 consecutive d postadmission</td>
<td valign="top">The placebo preparation consisted of identical doses of powdered glucose polymer</td>
<td valign="top">CDC definitions</td>
<td valign="top">New or progressive pulmonary radiological infiltrate, purulent tracheal secretions, fever (&gt;38.5°C), and leucocytosis or leucopenia (white blood cell count &gt;12 × 10<sup>9</sup> L<sup>–1</sup> or &lt;4 × 10<sup>9</sup> L<sup>–1</sup>)</td>
</tr>
<tr>
<td valign="top">Spindler-Vesel (2007)<sup><xref ref-type="bibr" rid="bibr25-0148607112463245">25</xref></sup></td>
<td valign="top">113 (26/87)</td>
<td valign="top">RCT/2</td>
<td valign="top">Multiple injured patients, with an Injury Severity Score of &gt;18 and at least a 4-d ICU stay</td>
<td valign="top">Standard enteral formula with fibers combined with Synbiotic 2000FORTEP containing 10<sup>10</sup> <italic>P pentosaceus</italic> 5–33:3, 10<sup>10</sup> <italic>L mesenteroides</italic> 32–77:1, 10<sup>10</sup> <italic>L paracasei</italic> ssp 19, and 10<sup>10</sup> <italic>L plantarum</italic> 2362</td>
<td valign="top">Glutamine, fermentable fiber, peptide diet</td>
<td valign="top">CDC definitions</td>
<td valign="top">New or progressive pulmonary radiological infiltrate, plus at least 2 clinical features: (1) temperature &gt;38°C, (2) leukocytosis &gt;10,000 cells/mm<sup>3</sup>, and (3) purulent respiratory secretions</td>
</tr>
<tr>
<td valign="top">Tan (2011)<sup><xref ref-type="bibr" rid="bibr26-0148607112463245">26</xref></sup></td>
<td valign="top">52 (26/26)</td>
<td valign="top">RCT/3</td>
<td valign="top">Brain injury alone patients, ages 18–60 years, admission within 24 h after trauma, with Glasgow score from 5–8 and able to be fed via nasogastric tube within 48 h after admission</td>
<td valign="top">Enteral nutrition plus 10<sup>9</sup> probiotics containing 0.5 × 10<sup>8</sup> <italic>Bifidobacterium longum</italic>, 0.5 × 10<sup>7</sup> <italic>Lactobacillus bulgaricus</italic>, and 0.5 × 10<sup>7</sup> <italic>Streptococcus thermophilus</italic>, 3 times a day, via a nasogastric tube or orally, for 21 consecutive d</td>
<td valign="top">Enteral nutrition (3.8 g protein, 13.8 g carbohydrate, 3.4 g fat/100 mL, osmolarity 250 mOsm/L, no fiber)</td>
<td valign="top">CDC definitions</td>
<td valign="top">New or progressive radiographic infiltrate plus at least 2 clinical features: temperature &gt;38°C, leukocytosis (white blood cells count &gt;12 × 10<sup>9</sup> L<sup>–1</sup>), leucopenia (white blood cells count &lt;4 × 10<sup>9</sup> L<sup>–1</sup>), or purulent tracheobronchial secretions and positive semiquantitative cultures of tracheobronchial secretions</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0148607112463245">
<p>CDC, Centers for Disease Control and Prevention; CFU, colony-forming unit; ICU, intensive care unit; NA, not available; RCT, randomized controlled trial; TISS, therapeutic intervention scoring system; VAP, ventilator-associated pneumonia.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-0148607112463245" position="float">
<label>Table 2.</label>
<caption><p>Outcome Data of Randomized Controlled Trials Included in the Meta-Analysis of Probiotics in Trauma Patients.</p></caption>
<graphic alternate-form-of="table2-0148607112463245" xlink:href="10.1177_0148607112463245-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="2">Nosocomial Infections, n/N<hr/></th>
<th align="center" colspan="2">VAP, n/N<hr/></th>
<th align="center" colspan="2">Mortality, n/N<hr/></th>
<th align="center" colspan="2">Length of ICU Stay, d<hr/></th>
</tr>
<tr>
<th align="left">First Author (Year of Publication)</th>
<th align="center">Probiotics</th>
<th align="center">Control</th>
<th align="center">Probiotics</th>
<th align="center">Control</th>
<th align="center">Probiotics</th>
<th align="center">Control</th>
<th align="center">Probiotics</th>
<th align="center">Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>Falcao de Arruda (2004)<sup><xref ref-type="bibr" rid="bibr22-0148607112463245">22</xref></sup></td>
<td>5/10</td>
<td>10/10</td>
<td>NA</td>
<td>NA</td>
<td>0/10</td>
<td>0/10</td>
<td>10 (5–20)</td>
<td>22 (7–57)</td>
</tr>
<tr>
<td>Olguin (2005)<sup><xref ref-type="bibr" rid="bibr23-0148607112463245">23</xref></sup></td>
<td>14/16</td>
<td>14/15</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Kotzampassi (2006)<sup><xref ref-type="bibr" rid="bibr24-0148607112463245">24</xref></sup></td>
<td>22/35</td>
<td>27/30</td>
<td>19/35</td>
<td>24/30</td>
<td>5/35</td>
<td>9/30</td>
<td>27.7 ± 15.2</td>
<td>41.3 ± 20.5</td>
</tr>
<tr>
<td>Spindler-Vesel (2007)<sup><xref ref-type="bibr" rid="bibr25-0148607112463245">25</xref></sup></td>
<td>5/26</td>
<td>46/87</td>
<td>4/26</td>
<td>34/87</td>
<td>2/26</td>
<td>5/87</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Tan (2011)<sup><xref ref-type="bibr" rid="bibr26-0148607112463245">26</xref></sup></td>
<td>9/26</td>
<td>15/26</td>
<td>7/16</td>
<td>13/19</td>
<td>3/26</td>
<td>5/26</td>
<td>6.8 ± 3.8</td>
<td>10.7 ± 7.3</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0148607112463245">
<p>ICU, intensive care unit; NA, not available; VAP, ventilator-associated pneumonia.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Of the 5 studies included in the meta-analysis, 2 included patients with multiple injuries,<sup><xref ref-type="bibr" rid="bibr24-0148607112463245">24</xref>,<xref ref-type="bibr" rid="bibr25-0148607112463245">25</xref></sup> 2 included patients with brain injury alone,<sup><xref ref-type="bibr" rid="bibr22-0148607112463245">22</xref>,<xref ref-type="bibr" rid="bibr26-0148607112463245">26</xref></sup> and 1 included burn patients.<sup><xref ref-type="bibr" rid="bibr23-0148607112463245">23</xref></sup> Two of the studies used synbiotic 2000FORTEP (Medipharm Kågerod, Sweden),<sup><xref ref-type="bibr" rid="bibr24-0148607112463245">24</xref>,<xref ref-type="bibr" rid="bibr25-0148607112463245">25</xref></sup> 2 used probiotics,<sup><xref ref-type="bibr" rid="bibr22-0148607112463245">22</xref>,<xref ref-type="bibr" rid="bibr26-0148607112463245">26</xref></sup> and 1 used a prebiotic (oligofructose).<sup><xref ref-type="bibr" rid="bibr23-0148607112463245">23</xref></sup> The definition of nosocomial infections and the diagnosis of VAP were available in 3 studies.<sup><xref ref-type="bibr" rid="bibr24-0148607112463245">24</xref><xref ref-type="bibr" rid="bibr25-0148607112463245"/>-<xref ref-type="bibr" rid="bibr26-0148607112463245">26</xref></sup></p>
</sec>
<sec id="section11-0148607112463245">
<title>Primary Outcome: Nosocomial Infections</title>
<p>All 5 RCTs reported nosocomial infections in study patients. The aggregated results of these studies suggest that the use of probiotics reduced the incidence of nosocomial infections (RR, 0.65; 95% CI, 0.45–0.94; <italic>P</italic> = .02; <xref ref-type="fig" rid="fig2-0148607112463245">Figure 2</xref>). The test for heterogeneity was significant (<italic>I</italic><sup>2</sup> = 73.3%).</p>
<fig id="fig2-0148607112463245" position="float">
<label>Figure 2.</label>
<caption><p>Meta-analysis of randomized controlled trials evaluating effect of probiotics on the incidence of nosocomial infections. CI, confidence interval; RR, relative risk.</p></caption>
<graphic xlink:href="10.1177_0148607112463245-fig2.tif"/>
</fig>
<p>Subsequently, we performed sensitivity analyses to explore potential source of heterogeneity. Exclusion of 2 studies that had a modest sample size (N ≤ 50) yielded similar results (RR, 0.57; 95% CI, 0.42–0.76; <italic>P</italic> &lt; .001), with moderate heterogeneity (<italic>I</italic><sup>2</sup> = 39.1%).<sup><xref ref-type="bibr" rid="bibr22-0148607112463245">22</xref>,<xref ref-type="bibr" rid="bibr23-0148607112463245">23</xref></sup> Exclusion of 2 studies with low quality (Jadad score ≤2) changed the pooled results substantially (RR, 0.77; 95% CI, 0.57–1.05; <italic>P</italic> = .04), yet heterogeneity was still present (<italic>I</italic><sup>2</sup> = 59.7%).<sup><xref ref-type="bibr" rid="bibr22-0148607112463245">22</xref>,<xref ref-type="bibr" rid="bibr25-0148607112463245">25</xref></sup> Exclusion of 1 study that enrolled burn patients changed the overall estimate a little (RR, 0.56; 95% CI, 0.43–0.73; <italic>P</italic> &lt; .001), but almost no evidence of heterogeneity was observed among the remaining studies (<italic>I</italic><sup>2</sup> = 14.6%).<sup><xref ref-type="bibr" rid="bibr23-0148607112463245">23</xref></sup></p>
</sec>
<sec id="section12-0148607112463245">
<title>Secondary Outcomes: VAP, Length of ICU Stay, and Mortality</title>
<p>The incidence of VAP and the length of ICU stay were lower among patients receiving probiotics than in the control group (3 RCTs; RR, 0.59; 95% CI, 0.42–0.81; <italic>P</italic> = .001; <xref ref-type="fig" rid="fig3-0148607112463245">Figure 3</xref>; 2 RCTs, SMD, −0.71 days; 95% CI, −1.09 to −0.34; <italic>P</italic> &lt; .001; <xref ref-type="fig" rid="fig4-0148607112463245">Figure 4</xref>, respectively), whereas mortality was not different between patients of the compared groups (3 RCTs; RR, 0.63; 95% CI, 0.32–1.26; <italic>P</italic> = .19; <xref ref-type="fig" rid="fig5-0148607112463245">Figure 5</xref>). There was no evidence of heterogeneity for these secondary outcomes (<italic>I</italic><sup>2</sup> = 0.0%).</p>
<fig id="fig3-0148607112463245" position="float">
<label>Figure 3.</label>
<caption><p>Meta-analysis of randomized controlled trials evaluating effect of probiotics on the incidence of ventilator-associated pneumonia. CI, confidence interval; RR, relative risk.</p></caption>
<graphic xlink:href="10.1177_0148607112463245-fig3.tif"/>
</fig>
<fig id="fig4-0148607112463245" position="float">
<label>Figure 4.</label>
<caption><p>Meta-analysis of randomized controlled trials evaluating effect of probiotics on length of intensive care unit stay. CI, confidence interval; SMD, standardized mean difference.</p></caption>
<graphic xlink:href="10.1177_0148607112463245-fig4.tif"/>
</fig>
<fig id="fig5-0148607112463245" position="float">
<label>Figure 5.</label>
<caption><p>Meta-analysis of randomized controlled trials evaluating effect of probiotics on mortality. CI, confidence interval; RR, relative risk.</p></caption>
<graphic xlink:href="10.1177_0148607112463245-fig5.tif"/>
</fig>
</sec>
<sec id="section13-0148607112463245">
<title>Publication Bias</title>
<p>Publication bias was not assessed because of the limited number (&lt;10) of studies included in each analysis.</p>
</sec>
</sec>
<sec id="section14-0148607112463245" sec-type="discussion">
<title>Discussion</title>
<p>To the best of our knowledge, this is the first meta-analysis to explore the role of probiotics in trauma patients. The pooled results from the meta-analysis of 5 RCTs using a random-effects model suggest that the use of probiotics reduced the incidence of nosocomial infections by 35% in trauma patients. In addition, probiotics seemed to lower the incidence of VAP and length of ICU stay but did not lower mortality more than the control group.</p>
<p>Nosocomial infections occur frequently in trauma patients.<sup><xref ref-type="bibr" rid="bibr27-0148607112463245">27</xref></sup> The present meta-analysis indicated that the use of probiotics was associated with a reduction in the incidence of nosocomial infections. However, substantial heterogeneity was observed among these studies, which was not surprising given the differences in characteristics of populations, regimen and composition of probiotics, and study designs. Our sensitivity analyses suggest that 1 trial conducted in burn patients probably contributed to the heterogeneity.<sup><xref ref-type="bibr" rid="bibr23-0148607112463245">23</xref></sup> In addition to the differences in the features of the study populations, this study also differed from others in some aspects. On one hand, the small number of cases and participants increased the possibility that chance accounted for their results, but on the other hand, the major purpose of this trial focuses on gastrointestinal barrier function instead of infection.</p>
<p>Our study provides additional interesting clues that may be useful for future research on the topic. Remarkably, 2 RCTs included in our meta-analysis enrolled only patients with brain injury.<sup><xref ref-type="bibr" rid="bibr22-0148607112463245">22</xref>,<xref ref-type="bibr" rid="bibr26-0148607112463245">26</xref></sup> The pooled RR using a fixed-effects model meta-analysis was 0.57 (95% CI, 0.36–0.89; <italic>P</italic> = .01; <italic>I</italic><sup>2</sup> = 0.0%), which suggests that the incidence of nosocomial infections was also decreased in this subgroup analysis. Thus, one may focus on this specific patient population—namely, patients with brain injury—when studying the protective effect of probiotics against nosocomial infection.</p>
<p>Another interesting finding is that the incidence of VAP was significantly lower and the length of ICU stay was significantly shorter among trauma patients receiving probiotics. The ability to reduce length of ICU stay provides more compelling evidence of a tangible benefit for clinicians than simply reducing infectious complications. This is of great importance since shorter length of ICU stay may reduce the risk of hospital infection and result in financial benefit. None of the identified RCTs provided a cost-effectiveness analysis; thus, this may be an interesting focus for future studies.</p>
<p>Our meta-analysis indicated that the use of probiotics shows a tendency to reduce mortality but confers no statistically significant benefit in mortality. In fact, these results are not conclusive inasmuch as they are not adequately powered to examine the effect of probiotics on mortality. Mortality was not regarded as the primary outcome and was the only clinically significant end point consistently reported in many of the studies included in this meta-analysis. In addition, only 3 RCTs with a modest sample size provided data on mortality; additional studies are warranted.</p>
<p>Most of the included RCTs did not report adverse effects of probiotics therapy during the study period. Only 1 trial reported minor side effects, such as diarrhea and other gastrointestinal complications.<sup><xref ref-type="bibr" rid="bibr24-0148607112463245">24</xref></sup> This is partly because this study enrolled patients with severe multiple trauma who were critically ill and often immunosuppressed. Although generally regarded as safe and well tolerated by most patients and physicians, it should be noted that probiotics may induce colonization and carry probiotics-related disease in the host, especially in severe trauma patients, since probiotics are viable organisms and patients with severe trauma represent a vulnerable population. Besselink et al<sup><xref ref-type="bibr" rid="bibr28-0148607112463245">28</xref></sup> reported that patients with severe acute pancreatitis who received probiotics had more infectious complications as well as an increased risk of mortality compared with patients who received a placebo. Endocarditis and bacteremia caused by probiotics also have been reported.<sup><xref ref-type="bibr" rid="bibr29-0148607112463245">29</xref>,<xref ref-type="bibr" rid="bibr30-0148607112463245">30</xref></sup></p>
<p>This meta-analysis has several potential limitations that should be taken into account. First, the characteristics of populations, the probiotic regimen (species, dosage, route, timing, and duration of administration), and the study designs vary considerably among the reviewed studies. These factors may result in heterogeneity and have a potential impact on our results. Second, the control groups may or may not have included glutamine and other substances that were not presented in the experiment group, making it difficult to address the isolated effect of probiotics. Furthermore, our analysis is based on only 5 RCTs, and most of them have a modest sample size. Finally, we are unable to assess the impact of probiotics on other clinically meaningful end points, such as length of the hospital stay and antibiotic consumption, because of sparse and inconsistent reporting across trials.</p>
<p>Further studies should focus on the following points. There is a need to standardize a probiotics protocol (ie, further consistency regarding species, dosage, route, timing, and duration of administration) since great variability exists in the literature. Next, the synergistic effects of other coexisting substances and probiotics on the clinical outcomes of trauma patients need to be excluded. Finally, although probiotics are generally considered safe and well tolerated, future studies should pay more attention to the safety of probiotics.</p>
<p>In conclusion, the current limited evidence suggests that the use of probiotics may reduce the incidence of nosocomial infections, VAP, and length of ICU stay in trauma patients. Despite these encouraging findings, the results should be interpreted with caution due to the heterogeneity among study designs. Further large-scale, well-designed RCTs on this topic are still needed. In such future studies, the safety of probiotics also should be given more attention.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: none declared.</p>
</fn>
<fn fn-type="other">
<p>This article originally appeared online on October 12, 2012.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0148607112463245">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schrezenmeir</surname><given-names>J</given-names></name>
<name><surname>de Vrese</surname><given-names>M</given-names></name>
</person-group>. <article-title>Probiotics, prebiotics, and synbiotics—approaching a definition</article-title>. <source>Am J Clin Nutr</source>. <year>2001</year>;<volume>73</volume>:<fpage>361S</fpage>–<lpage>364S</lpage>.</citation>
</ref>
<ref id="bibr2-0148607112463245">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wolvers</surname><given-names>D</given-names></name>
<name><surname>Antoine</surname><given-names>JM</given-names></name>
<name><surname>Myllyluoma</surname><given-names>E</given-names></name>
<name><surname>Schrezenmeir</surname><given-names>J</given-names></name>
<name><surname>Szajewska</surname><given-names>H</given-names></name>
<name><surname>Rijkers</surname><given-names>GT</given-names></name>
</person-group>. <article-title>Guidance for substantiating the evidence for beneficial effects of probiotics: prevention and management of infections by probiotics</article-title>. <source>J Nutr</source>. <year>2010</year>;<volume>140</volume>:<fpage>698S</fpage>–<lpage>712S</lpage>.</citation>
</ref>
<ref id="bibr3-0148607112463245">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Watkinson</surname><given-names>PJ</given-names></name>
<name><surname>Barber</surname><given-names>VS</given-names></name>
<name><surname>Dark</surname><given-names>P</given-names></name>
<name><surname>Young</surname><given-names>JD</given-names></name>
</person-group>. <article-title>The use of pre- pro- and synbiotics in adult intensive care unit patients: systematic review</article-title>. <source>Clin Nutr</source>. <year>2007</year>;<volume>26</volume>:<fpage>182</fpage>–<lpage>192</lpage>.</citation>
</ref>
<ref id="bibr4-0148607112463245">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Siempos</surname></name>
<name><surname>Ntaidou</surname><given-names>TK</given-names></name>
<name><surname>Falagas</surname><given-names>ME</given-names></name>
</person-group>. <article-title>Impact of the administration of probiotics on the incidence of ventilator-associated pneumonia: a meta-analysis of randomized controlled trials</article-title>. <source>Crit Care Med</source>. <year>2010</year>;<volume>38</volume>:<fpage>954</fpage>–<lpage>962</lpage>.</citation>
</ref>
<ref id="bibr5-0148607112463245">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pitsouni</surname><given-names>E</given-names></name>
<name><surname>Alexiou</surname><given-names>V</given-names></name>
<name><surname>Saridakis</surname><given-names>V</given-names></name>
<name><surname>Peppas</surname><given-names>G</given-names></name>
<name><surname>Falagas</surname><given-names>ME</given-names></name>
</person-group>. <article-title>Does the use of probiotics/synbiotics prevent postoperative infections in patients undergoing abdominal surgery? A meta-analysis of randomized controlled trials</article-title>. <source>Eur J Clin Pharmacol</source>. <year>2009</year>;<volume>65</volume>:<fpage>561</fpage>–<lpage>570</lpage>.</citation>
</ref>
<ref id="bibr6-0148607112463245">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>MM</given-names></name>
<name><surname>Cheng</surname><given-names>JQ</given-names></name>
<name><surname>Lu</surname><given-names>YR</given-names></name>
<name><surname>Yi</surname><given-names>ZH</given-names></name>
<name><surname>Yang</surname><given-names>P</given-names></name>
<name><surname>Wu</surname><given-names>XT</given-names></name>
</person-group>. <article-title>Use of pre-, pro- and synbiotics in patients with acute pancreatitis: a meta-analysis</article-title>. <source>World J Gastroenterol</source>. <year>2010</year>;<volume>16</volume>:<fpage>3970</fpage>–<lpage>3978</lpage>.</citation>
</ref>
<ref id="bibr7-0148607112463245">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Evans</surname><given-names>C</given-names></name>
<name><surname>Howes</surname><given-names>D</given-names></name>
<name><surname>Pickett</surname><given-names>W</given-names></name>
<name><surname>Dagnone</surname><given-names>L</given-names></name>
</person-group>. <article-title>Audit filters for improving processes of care and clinical outcomes in trauma systems</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2009</year>;(<issue>4</issue>):<fpage>CD007590</fpage>.</citation>
</ref>
<ref id="bibr8-0148607112463245">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Maio</surname><given-names>RF</given-names></name>
<name><surname>Garrison</surname><given-names>HG</given-names></name>
<name><surname>Spaite</surname><given-names>DW</given-names></name>
<etal/>
</person-group>. <article-title>Emergency Medical Services Outcomes Project I (EMSOP I): prioritizing conditions for outcomes research</article-title>. <source>Ann Emerg Med</source>. <year>1999</year>;<volume>33</volume>:<fpage>423</fpage>–<lpage>432</lpage>.</citation>
</ref>
<ref id="bibr9-0148607112463245">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stiell</surname><given-names>IG</given-names></name>
<name><surname>Nesbitt</surname><given-names>LP</given-names></name>
<name><surname>Pickett</surname><given-names>W</given-names></name>
<etal/>
</person-group>. <article-title>The OPALS Major Trauma Study: impact of advanced life-support on survival and morbidity</article-title>. <source>CMAJ</source>. <year>2008</year>;<volume>178</volume>:<fpage>1141</fpage>–<lpage>1152</lpage>.</citation>
</ref>
<ref id="bibr10-0148607112463245">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morgan</surname><given-names>AS</given-names></name>
</person-group>. <article-title>Risk factors for infection in the trauma patient</article-title>. <source>J Natl Med Assoc</source>. <year>1992</year>;<volume>84</volume>:<fpage>1019</fpage>–<lpage>1023</lpage>.</citation>
</ref>
<ref id="bibr11-0148607112463245">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Garner</surname><given-names>JS</given-names></name>
<name><surname>Jarvis</surname><given-names>WR</given-names></name>
<name><surname>Emori</surname><given-names>TG</given-names></name>
<name><surname>Horan</surname><given-names>TC</given-names></name>
<name><surname>Hughes</surname><given-names>JM</given-names></name>
</person-group>. <article-title>CDC definitions for nosocomial infections, 1988</article-title>. <source>Am J Infect Control</source>. <year>1988</year>;<volume>16</volume>:<fpage>128</fpage>–<lpage>140</lpage>.</citation>
</ref>
<ref id="bibr12-0148607112463245">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jadad</surname><given-names>AR</given-names></name>
<name><surname>Moore</surname><given-names>RA</given-names></name>
<name><surname>Carroll</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</article-title> <source>Control Clin Trials</source>. <year>1996</year>;<volume>17</volume>:<fpage>1</fpage>–<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr13-0148607112463245">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kjaergard</surname><given-names>LL</given-names></name>
<name><surname>Villumsen</surname><given-names>J</given-names></name>
<name><surname>Gluud</surname><given-names>C</given-names></name>
</person-group>. <article-title>Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses</article-title>. <source>Ann Intern Med</source>. <year>2001</year>;<volume>135</volume>:<fpage>982</fpage>–<lpage>989</lpage>.</citation>
</ref>
<ref id="bibr14-0148607112463245">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Higgins</surname><given-names>JP</given-names></name>
<name><surname>Thompson</surname><given-names>SG</given-names></name>
<name><surname>Deeks</surname><given-names>JJ</given-names></name>
<name><surname>Altman</surname><given-names>DG</given-names></name>
</person-group>. <article-title>Measuring inconsistency in meta-analyses</article-title>. <source>BMJ</source>. <year>2003</year>;<volume>327</volume>:<fpage>557</fpage>–<lpage>560</lpage>.</citation>
</ref>
<ref id="bibr15-0148607112463245">
<label>15.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Armitage</surname><given-names>P</given-names></name>
<name><surname>Berry</surname><given-names>G</given-names></name>
<name><surname>Matthews</surname><given-names>JNS</given-names></name>
</person-group>. <article-title>Analysing means and proportions</article-title>. In: <source>Statistical Methods in Medical Research</source>. <publisher-loc>Oxford, UK</publisher-loc>: <publisher-name>Blackwell Science</publisher-name>; <year>2002</year>:<fpage>83</fpage>–<lpage>146</lpage>.</citation>
</ref>
<ref id="bibr16-0148607112463245">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Begg</surname><given-names>CB</given-names></name>
<name><surname>Mazumdar</surname><given-names>M</given-names></name>
</person-group>. <article-title>Operating characteristics of a rank correlation test for publication bias</article-title>. <source>Biometrics</source>. <year>1994</year>;<volume>50</volume>:<fpage>1088</fpage>–<lpage>1101</lpage>.</citation>
</ref>
<ref id="bibr17-0148607112463245">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Egger</surname><given-names>M</given-names></name>
<name><surname>Davey Smith</surname><given-names>G</given-names></name>
<name><surname>Schneider</surname><given-names>M</given-names></name>
<name><surname>Minder</surname><given-names>C</given-names></name>
</person-group>. <article-title>Bias in meta-analysis detected by a simple, graphical test</article-title>. <source>BMJ</source>. <year>1997</year>;<volume>315</volume>:<fpage>629</fpage>–<lpage>634</lpage>.</citation>
</ref>
<ref id="bibr18-0148607112463245">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Koutelidakis</surname><given-names>IM</given-names></name>
<name><surname>Bezirtzoglou</surname><given-names>E</given-names></name>
<name><surname>Giamarellos-Bourboulis</surname><given-names>EJ</given-names></name>
<name><surname>Grosomanidis</surname><given-names>V</given-names></name>
<name><surname>Kotzampassi</surname><given-names>K</given-names></name>
</person-group>. <article-title>Impact of synbiotics on the intestinal flora of critically ill patients with multiple injuries</article-title>. <source>Int J Antimicrob Agents</source>. <year>2010</year>;<volume>36</volume>:<fpage>90</fpage>–<lpage>91</lpage>.</citation>
</ref>
<ref id="bibr19-0148607112463245">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lu</surname><given-names>X</given-names></name>
<name><surname>Han</surname><given-names>CM</given-names></name>
<name><surname>Yu</surname><given-names>JX</given-names></name>
<name><surname>Fu</surname><given-names>SZ</given-names></name>
</person-group>. <article-title>Preliminary comparative study on the effects of early enteral supplementation of synbiotics on severely burned patients [in Chinese]</article-title>. <source>Zhonghua Shao Shang Za Zhi</source>. <year>2004</year>;<volume>20</volume>:<fpage>198</fpage>–<lpage>201</lpage>.</citation>
</ref>
<ref id="bibr20-0148607112463245">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Peral</surname><given-names>MC</given-names></name>
<name><surname>Martinez</surname><given-names>MA</given-names></name>
<name><surname>Valdez</surname><given-names>JC</given-names></name>
</person-group>. <article-title>Bacteriotherapy with <italic>Lactobacillus plantarum</italic> in burns</article-title>. <source>Int Wound J</source>. <year>2009</year>;<volume>6</volume>:<fpage>73</fpage>–<lpage>81</lpage>.</citation>
</ref>
<ref id="bibr21-0148607112463245">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Giamarellos-Bourboulis</surname><given-names>EJ</given-names></name>
<name><surname>Bengmark</surname><given-names>S</given-names></name>
<name><surname>Kanellakopoulou</surname><given-names>K</given-names></name>
<name><surname>Kotzampassi</surname><given-names>K</given-names></name>
</person-group>. <article-title>Pro- and synbiotics to control inflammation and infection in patients with multiple injuries</article-title>. <source>J Trauma</source>. <year>2009</year>;<volume>67</volume>:<fpage>815</fpage>–<lpage>821</lpage>.</citation>
</ref>
<ref id="bibr22-0148607112463245">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Falcao</surname><given-names>de</given-names></name>
<name><surname>Arruda</surname><given-names>IS</given-names></name>
<name><surname>de Aguilar-Nascimento</surname><given-names>JE</given-names></name>
</person-group>. <article-title>Benefits of early enteral nutrition with glutamine and probiotics in brain injury patients</article-title>. <source>Clin Sci (Lond)</source>. <year>2004</year>;<volume>106</volume>:<fpage>287</fpage>–<lpage>292</lpage>.</citation>
</ref>
<ref id="bibr23-0148607112463245">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Olguin</surname><given-names>F</given-names></name>
<name><surname>Araya</surname><given-names>M</given-names></name>
<name><surname>Hirsch</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Prebiotic ingestion does not improve gastrointestinal barrier function in burn patients</article-title>. <source>Burns</source>. <year>2005</year>;<volume>31</volume>:<fpage>482</fpage>–<lpage>488</lpage>.</citation>
</ref>
<ref id="bibr24-0148607112463245">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kotzampassi</surname><given-names>K</given-names></name>
<name><surname>Giamarellos-Bourboulis</surname><given-names>EJ</given-names></name>
<name><surname>Voudouris</surname><given-names>A</given-names></name>
<name><surname>Kazamias</surname><given-names>P</given-names></name>
<name><surname>Eleftheriadis</surname><given-names>E</given-names></name>
</person-group>. <article-title>Benefits of a synbiotic formula (Synbiotic 2000Forte) in critically Ill trauma patients: early results of a randomized controlled trial</article-title>. <source>World J Surg</source>. <year>2006</year>;<volume>30</volume>:<fpage>1848</fpage>–<lpage>1855</lpage>.</citation>
</ref>
<ref id="bibr25-0148607112463245">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Spindler-Vesel</surname><given-names>A</given-names></name>
<name><surname>Bengmark</surname><given-names>S</given-names></name>
<name><surname>Vovk</surname><given-names>I</given-names></name>
<name><surname>Cerovic</surname><given-names>O</given-names></name>
<name><surname>Kompan</surname><given-names>L</given-names></name>
</person-group>. <article-title>Synbiotics, prebiotics, glutamine, or peptide in early enteral nutrition: a randomized study in trauma patients</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2007</year>;<volume>31</volume>:<fpage>119</fpage>–<lpage>126</lpage>.</citation>
</ref>
<ref id="bibr26-0148607112463245">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tan</surname><given-names>M</given-names></name>
<name><surname>Zhu</surname><given-names>JC</given-names></name>
<name><surname>Du</surname><given-names>J</given-names></name>
<name><surname>Zhang</surname><given-names>LM</given-names></name>
<name><surname>Yin</surname><given-names>HH</given-names></name>
</person-group>. <article-title>Effects of probiotics on serum levels of Th1/Th2 cytokine and clinical outcomes in severe traumatic brain-injured patients: a prospective randomized pilot study</article-title>. <source>Crit Care</source>. <year>2011</year>;<volume>15</volume>:<fpage>R290</fpage>.</citation>
</ref>
<ref id="bibr27-0148607112463245">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lazarus</surname><given-names>HM</given-names></name>
<name><surname>Fox</surname><given-names>J</given-names></name>
<name><surname>Lloyd</surname><given-names>JF</given-names></name>
<etal/>
</person-group>. <article-title>A six-year descriptive study of hospital-associated infection in trauma patients: demographics, injury features, and infection patterns</article-title>. <source>Surg Infect (Larchmt)</source>. <year>2007</year>;<volume>8</volume>:<fpage>463</fpage>–<lpage>473</lpage>.</citation>
</ref>
<ref id="bibr28-0148607112463245">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Besselink</surname><given-names>MG</given-names></name>
<name><surname>van Santvoort</surname><given-names>HC</given-names></name>
<name><surname>Buskens</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial</article-title>. <source>Lancet</source>. <year>2008</year>;<volume>371</volume>:<fpage>651</fpage>–<lpage>659</lpage>.</citation>
</ref>
<ref id="bibr29-0148607112463245">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Soleman</surname><given-names>N</given-names></name>
<name><surname>Laferl</surname><given-names>H</given-names></name>
<name><surname>Kneifel</surname><given-names>W</given-names></name>
<etal/>
</person-group>. <article-title>How safe is safe?—a case of <italic>Lactobacillus paracasei</italic> ssp. paracasei endocarditis and discussion of the safety of lactic acid bacteria</article-title>. <source>Scand J Infect Dis</source>. <year>2003</year>;<volume>35</volume>:<fpage>759</fpage>–<lpage>762</lpage>.</citation>
</ref>
<ref id="bibr30-0148607112463245">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kunz</surname><given-names>AN</given-names></name>
<name><surname>Noel</surname><given-names>JM</given-names></name>
<name><surname>Fairchok</surname><given-names>MP</given-names></name>
</person-group>. <article-title>Two cases of <italic>Lactobacillus bacteremia</italic> during probiotic treatment of short gut syndrome</article-title>. <source>J Pediatr Gastroenterol Nutr</source>. <year>2004</year>;<volume>38</volume>:<fpage>457</fpage>–<lpage>458</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>